您当前的位置：

(±)-Zanubrutinib

(Synonyms: (±)-泽布替尼; (±)-BGB-3111)

目录号: PL01231 纯度: ≥99%

(±)-Zanubrutinib ((±)-BGB-3111) 是一种有效选择性的，具有口服活性的 Bruton's 酪氨酸激酶 (Btk) 抑制剂。

CAS No. :1633350-06-7

商品编号	规格	价格	会员价
PL01231-5mg	5mg	¥788.00	请登录
PL01231-10mg	10mg	¥1315.00	请登录
PL01231-50mg	50mg	¥3685.00	请登录
PL01231-100mg	100mg	¥5225.00	请登录
PL01231-200mg	200mg	¥7185.00	请登录
PL01231-10mM*1mLinDMSO	10mM*1mLinDMSO	¥2210.00	请登录
PL01231-1 mL x 10 mM (in DMSO)		¥837.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

*注意事项:下单时请联系销售核实产品价格及货期，避免后续产生不便，感谢支持!

加入购物车在线咨询收藏产品大包装询价

中文名称	(±)-Zanubrutinib
英文名称	(±)-Zanubrutinib
英文别名	7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide;BGB3111;(+/-)-Zanubrutinib;((plusmn))-Zanubrutinib;2-(4-phenoxyphenyl)-7-(1-prop-2-enoylpiperidin-4-yl)-1,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide;BDBM249900;BCP25045;BCP25838;NSC799318;SB18877;( inverted exclamation markA)-Zanubrutinib;US9447106, 27;C(C=C)(=O)N1CCC(CC1)C1CCNC=2N1N=C(C;(±)-Zanubrutinib
Cas No.	1633350-06-7
分子式	C₂₇H₂₉N₅O₃
分子量	471.55
包装储存	Powder -20°C 3 years；4°C 2 years
详情描述	(±)-Zanubrutinib ((±)-BGB-3111) 是一种有效选择性的，具有口服活性的 Bruton's 酪氨酸激酶 (Btk) 抑制剂。

产品详情	(±)-Zanubrutinib ((±)-BGB-3111) 是一种有效选择性的，具有口服活性的 Bruton's 酪氨酸激酶 (Btk) 抑制剂。
生物活性	(±)-Zanubrutinib ((±)-BGB-3111) is a potent, selective and orally available Brutons tyrosine kinase (Btk) inhibitor.
性状	Solid
体外研究(In Vitro)	In both biochemical and cellular assays, (±)-Zanubrutinib ((±)-BGB-3111) demonstrates nanomolar Btk inhibition activity. In several MCL and DLBCL cell lines, (±)-Zanubrutinib inhibits BCR aggregation-triggered Btk autophosphorylation, blocks downstream PLC-γ2 signaling, and potently inhibits cell proliferation. In comparison with PCI-32765, (±)-Zanubrutinib shows much more restricted off-target activities against a panel of kinases, including ITK. has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)	(±)-Zanubrutinib induces dose-dependent anti-tumor effects against REC-1 MCL xenografts engrafted either subcutaneously or systemically via tail vein injection in mice. In the subcutaneous xenografts. Preliminary 14-day toxicity study in rats shows that (±)-Zanubrutinib is very well tolerated and maximal tolerate dose (MTD) is not reached when it is dosed up to 250mg/kg/day. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Powder -20°C 3 years；4°C 2 years
参考文献	[1]. Na L, et al. BGB-3111 is a novel and highly selective Brutons tyrosine kinase (BTK) inhibitor. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): A

溶解度数据	In Vitro: DMSO : ≥ 30 mg/mL (63.62 mM)Ethanol : ≥ 10 mg/mL (21.21 mM)

搜索质检报告(COA)

产品使用指南

Data Sheet

[1]. Na L, et al. BGB-3111 is a novel and highly selective Brutons tyrosine kinase (BTK) inhibitor. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): A

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

(±)-Zanubrutinib

相关产品

The molarity calculator equation

The dilution calculator equation